Study Enrollment

Your details will not be published or shared.

Clinical Trial

(MELODY) A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants

This study is to evaluate a longer-acting vaccine to prevent RSV (Respiratory Syncytial Virus) in healthy neonates.

Eligibility Criteria

  • Inclusion Criteria: 1. Healthy pre-term and full-term infants who are entering their first RSV season Exclusion Criteria: 1. Any infants who have fever or acute illness within 7 days prior to randomization 2. Any infants who have or have a history of a lung infection or RSV infection 3.Any infant with a history of health problems 4. Children of employees of the sponsor or Augusta University

Contact Information

    Mutsa Seremwe

    (706) 721-0193